A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors?

Ann Hematol. 2018 Mar;97(3):545-546. doi: 10.1007/s00277-017-3172-x. Epub 2017 Nov 13.

Authors

T Cammaert¹, K Decaestecker², N Sundahl³, S Rottey⁴, K M J Devreese⁵

Affiliations

¹ Coagulation Laboratory, Ghent University Hospital, De Pintelaan, 185 (2P8), B-9000, Ghent, Belgium. [email protected].
² Department of Urology, University Hospital Ghent, De Pintelaan 185, 9000, Ghent, Belgium.
³ Department of Radiation-Oncology and Experimental Cancer Research, University Hospital Ghent, De Pintelaan 185, 9000, Ghent, Belgium.
⁴ Department of Medical Oncology, University Hospital Ghent, De Pintelaan 185, 9000, Ghent, Belgium.
⁵ Coagulation Laboratory, Ghent University Hospital, De Pintelaan, 185 (2P8), B-9000, Ghent, Belgium.

PMID: 29130135
DOI: 10.1007/s00277-017-3172-x

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents, Immunological / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Blood Coagulation Tests
Carcinoma, Transitional Cell / complications
Carcinoma, Transitional Cell / secondary*
Carcinoma, Transitional Cell / therapy
Combined Modality Therapy
Cystectomy
Factor X Deficiency / blood
Factor X Deficiency / etiology*
Humans
Lung Neoplasms / complications
Lung Neoplasms / secondary*
Lung Neoplasms / therapy
Male
Neoadjuvant Therapy
Neoplasm Metastasis / physiopathology*
Radiosurgery
Urinary Bladder Neoplasms / complications*
Urinary Bladder Neoplasms / therapy

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
pembrolizumab